Authentication of Nasopharyngeal Carcinoma Tumor Lines
Siu‐Ki Chan,Kwong‐Wai Choy,Sai‐Wah Tsao,Qian Tao,Tao Tang,Grace Tin‐Yun Chung,Kwok‐Wai Lo
DOI: https://doi.org/10.1002/ijc.23374
2008-01-01
International Journal of Cancer
Abstract:Nasopharyngeal carcinoma (NPC) is rare in most part of the world but shows high incidence in South China and Southeast Asia. One of the unique features of this epithelial cancer is its consistent association with Epstein–Barr virus (EBV) infection. Studies have shown that EBV plays a key role in the genesis and maintenance of the tumor phenotype in this disease.1 Clonal EBV genome and latent gene products are found in almost all cases of NPC expect for the keratinizing type of NPC from nonendemic areas. With the advance of molecular biology, knowledge of molecular alterations and EBV's function in NPC rapidly accumulated in the past 15 years.1, 2 However, most of these studies are based on the EBV-negative NPC cell lines established at 10–20 years ago. Until now, only a few NPC cell lines, such as C666-1, stably harboring the EBV genome were used as EBV-positive NPC model.3 In addition to the established NPC cell lines, several EBV-positive NPC transplants in nude mice (e.g. C15, C17, xeno-666, xeno-2117 and xeno-1915) were used for identifying the genetic alterations and delineating aberrant signal transduction pathways in NPC.4, 5 Because of the difficulties in manipulating target gene expression in these in vivo models, they are rarely used in functional studies. Recently, we have performed the array-based CGH analysis on a number of NPC cell lines, xenografts and primary tumors.6 We observed similar copy number aberrant patterns in some EBV-negative cell lines. Furthermore, these cell lines show distinct transcription profiles from the C666-1 cell line and NPC xenografts in microarray analysis (unpublished observations). It raised the concern for the identity of tumor lines used in NPC study. Thus, we investigated the authenticity of a number of NPC cell lines (C666-1, HK-1, CNE-1 and CNE-2), xenografts (xeno-666, xeno-2117, xeno-1915, C15 and C17) and immortalized nasopharyngeal epithelial cell lines (NP69 and NP460), which are commonly included in our previous works.1 The DNA samples from these tumors were extracted and subjected to DNA fingerprinting analysis using the AmpF/STR Identifiler® PCR Amplification Kit (Applied Biosystems, Foster City, USA). A total of 15 short tandem repeat (STR) loci (D3S1358, vWA, FGA, D8S1179, D21S11, D18S51, D5S818, D13S317, D7S820, D16S539, TH01, TPOX, CSF1P0, D2S1338, D19S433) were co-amplified in each sample and detected on an ABI 3100 Genetic Analyzer according to the manufacturer's protocol. Amelogenin loci at the sex chromosomes was also examined. The data were analyzed and allele(s) of each locus were determined by GeneScan and GeneMapper™ ID Software (Applied Biosystems, Foster City, USA). The STR profiles of NPC tumors and immortalized nasopharyngeal epithelial cell lines are shown in Table I. Distinct STR profiles were found in HK-1, NP69, NP460 and all EBV-positive xenografts (xeno-666, xeno-2117, xeno-1915, C15 and C17). The STR profile of xeno-666 and its devised cell line C666-1 are almost identical.3 In C666-1 cells, multiple alleles of D8S1179 and D21S11 loci were observed. It may be due to the microsatellite instability feature of this cell line. Surprisingly, we found high similarity between the STR profiles of 2 EBV-negative cell lines, CNE-1 and CNE-2. Complete identical alleles were detected in 12 out of 15 loci. Compared to CNE-1, gain of an extra allele at TPOX and loss of 1 allele at FGA and THO1 was observed in CNE-2. The minor allelic variations may be due to genetic instability or chromosomal aberrant during long-term in vivo culture. The finding implies that these 2 widely used EBV-negative cell lines are genetically identical and should be derived from a single cell line. Because many studies have shown that a number of cell lines were contaminated with HeLa,7 we then investigated whether CNE-1 and CNE-2 are contaminated with this common cell line. HeLa is a cell line devised from the glandular cancer of cervix, which contains the HPV-18 genome. Nevertheless, HPVs have not been detected in primary NPC tumors. We have examined the presence of E6/E7 sequence of HPV-18 in all NPC samples by PCR analysis. Interestingly, HPV-18 sequences were only found in the CNE-1 and CNE-2 cells (Fig. 1). Furthermore, we examined whether the STR profile of the HeLa is identical to that of the 2 EBV-negative NPC cell lines. The STR profile of HeLa determined was completely matched with that listed in the ATCC datasheet. While we compared the STR profiles among HeLa, CNE-1 and CNE-2, we noted that the CNE-1 and CNE-2 profiles contain at least 1 identical allele from HeLa for the 15 loci examined. Interestingly, in several loci (e.g. vWA, D8S1179, D7S820, CSF190, D19S433), only 1 of 2 alleles from HeLa was detected in the CNE-1 and CNE-2 genomes. The presence of partial genome of HeLa in CNE-1 and CNE-2 excludes the possibility that the cell lines are simply cross-contaminants of HeLa cells. Our previous cytogenetic study also did not found 2 heterogenous populations with distinct karyotypes in these EBV-negative NPC cell lines.8 Moreover, CNE-1 and CNE-2 contain identical p53 mutation (p53 Thr280), which is not found in HeLa. A specific p16 mutation (splicing acceptor site of exon 2) was also detected in CNE-1 and CNE-2, but not HeLa cells. Thus, we postulate that the STR profiles of these 2 EBV-negative NPC cell lines could be generated from fusion of HeLa with an unknown cell line by somatic cell hybridization. We have previously found that that there is no expression of CD19, a B-cell marker, in these 2 cell lines. It is likely that these cell lines are not somatic cell hybrid of HeLa and Burkitt's lymphoblastoid cells which are commonly used for the study of EBV function in epithelial cells, probably that hybrid was generated by contamination and fusion of HeLa with an NPC cell line originally reported. HPV18 and EBV infection in NPC cell lines and xenografts. By PCR analysis, E6/E7 sequences of HPV18 were detected in HeLa and 2 EBV-negative NPC cell lines, CNE-1 and CNE-2. The LMP-1 sequence was shown in C666-1 cells and all NPC xenografts (xeno-666, xeno-2117, xeno-1915, C15 and C17). The HPV18 and EBV sequences were not found in the well-differentiated NPC cell line HK-1. According to the published reports, CNE-1 and CNE-2 were originally established from the well-differentiated squamous carcinoma and poorly differentiated carcinoma, respectively.9, 10 They were derived from the tumors of 2 different Chinese patients at approximately 20 years ago. The CNE-2 was reported to be EBV-positive initially and the EBV genome was lost during passage. To confirm that the contamination is not unique in our laboratories, we examined independent CNE-1 and CNE-2 samples from other laboratories in Hong Kong and Singapore. Similar STR profiles were observed in all these samples although some minor allelic variations were present (Table I). The distinct allelic variations suggest that the cell lines may passage independently for a long period. We believe that the contamination occurred before early 1990s. Sun et al.11 have already mentioned that the CNE-1 and CNE-2 used in their laboratory were arisen from a single individual although the cell lines are different in morphology and in degree of tumorigenicity. Moreover, a specific p53 Thr280 mutation in both CNE-1 and CNE-2 were reported independently by them and our group at that time. The false EBV-negative NPC cell lines may be widespread and misused for NPC study under various names for decades. Aside from numerous biological and molecular studies, these EBV-negative cell lines were also used as in vitro NPC model for evaluating the efficiency of the therapeutic agents. Our major concern is that study on these false NPC cell lines may lead to invalid conclusions. Several controversial issues in the field may be generated from these misleading data. For examples, the p53 and p16 mutations identified in these cell lines are rare in primary NPC.11, 12 The genetic and epigenetic alterations reported in these cells should be evaluated in primary NPC and other EBV-positive NPC tumor lines. Furthermore, the problems may be inferior in the studies of the signal transduction and drug response in NPC cells. Because of different cell type microenvironment and the expression of HPV18 latent products, the findings obtained are not relevant to the EBV-positive NPC cells. The concerns for the misidentified cancer cell lines are arising in the science community. There are up to 36% of the cell lines misidentified or contaminated.7, 13, 14 Because NPC is rare in Western country, no study for authenticating NPC cell lines has been reported previously. Aside from CNE-1 and CNE-2, we are recruiting other EBV-negative NPC cell lines from different sources for DNA fingerprinting analysis. It is noted that this "CNE-1" STR profile occurs commonly in the "EBV-negative NPC cell lines" (e.g. HNE-1, HNE-2) although the finding needs to be confirmed in the independent samples from various sources. However, it is important for research groups working on NPC to investigate the authenticity of NPC cell lines used in their experiments. We strongly suggest that the NPC cell lines should be subjected to PCR analysis of HPV-18 and genotyping by STR analysis for verification. The methods are simple, reliable and commercially available. The genotyping information must be compared to the STR profiles of CNE1, CNE2 and NPC tumor lines reported here. Furthermore, the specific p53 and p16 mutations identified in our previous studies may also serve as markers for these contaminants.11, 12 It is also important to verify the identities of authenticated NPC cell lines regularly to exclude contamination during passage. We concluded that a single HeLa related somatic cell hybrid has been misidentified as EBV-negative NPC cell lines, which have been widely used in NPC research. Authentication of the tumor lines in NPC studies is needed to consolidate the relevant information on this unique EBV-positive epithelial cancer. Yours sincerely, Sylvia Yat-Yee Chan, Kwong-Wai Choy, Sai-Wah Tsao, Qian Tao, Tao Tang, Grace Ting-Yun Chung, Kwok-Wai Lo.